DIG
ALLO icon

DeepCurrents Investment Group’s Allogene Therapeutics ALLO Stock Holding History

DeepCurrents Investment Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-63,967
Closed -$156K – 145
2026
Q1 		$156K Buy
+63,967
New +$128K 0.01% 135

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

DeepCurrents Investment Group's ALLO Position: Q2 2026 in Review

DeepCurrents Investment Group sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 63,967 shares — an estimated $156K sold.

DeepCurrents Investment Group first reported a position in ALLO in Q1 2026 and held it in 1 quarter. The position peaked at $156K in Q1 2026. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • DeepCurrents Investment Group reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • DeepCurrents Investment Group sold 63,967 Allogene Therapeutics shares in Q2 2026, an estimated $156K.
  • DeepCurrents Investment Group first reported a position in Allogene Therapeutics in Q1 2026 and held it in 1 quarter.
  • DeepCurrents Investment Group's Allogene Therapeutics position peaked at $156K in Q1 2026.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on DeepCurrents Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.